Group 1: Core Insights - Jiangbei New District in Nanjing has evolved into a national-level innovation hub, recognized for its significant contributions to the biopharmaceutical industry and technology advancements [1][2] - The district is home to over 1,300 biopharmaceutical companies and more than 200 new drugs in development, positioning it as a key player in Jiangsu's biopharmaceutical sector [2][4] - Notable achievements include the first CAR-T drug for cross-border supply by Reindeer Biotech and the first nucleic acid drug ER2001 injection by Aima Biotech, showcasing the district's innovative capabilities [2][3] Group 2: Industry Developments - Jiangbei New District has established itself as a center for integrated circuit industries, hosting hundreds of related companies, including TSMC, and covering the entire supply chain from design to manufacturing [3][4] - The district has seen significant investments in biopharmaceuticals, with funds supporting companies like Vili Biotech, which has 14 innovative drug candidates, and the recent approval of new antiviral drugs [5][6] - The collaboration between Nanjing University and Jiangbei New District aims to foster talent and innovation in biopharmaceuticals, with plans to accommodate over 5,000 students and faculty [4][5] Group 3: Community and Infrastructure - The district is characterized by a high concentration of PhD holders, with over 30% of the local population in the Longshan community holding advanced degrees, contributing to a vibrant innovation ecosystem [6][7] - The establishment of Nanjing North Station as a major transportation hub is expected to enhance connectivity and attract resources, further supporting the district's growth as a technology and innovation center [8][9] - Jiangbei New District is committed to creating a comprehensive ecosystem that integrates education, research, industry, and application in the biopharmaceutical sector [5][6]